This research letter highlights a potential underrecognized safety signal of increased red blood cell transfusion associated with albumin therapy in critically ill patients, emphasizing the role of hemodilution and the importance of reporting transfusion exposure and long-term outcomes in future randomized trials involving albumin administration.
Raffaele Mandarano
- Department of Anesthesia and Critical Care, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
https://orcid.org/0000-0002-4721-0537
Stefano Romagnoli
- Department of Anesthesia and Critical Care, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy; Department of Health Sciences (DSS), Section of Anesthesiology, Intensive Care and Pain Medicine, University of Florence, Florence, Italy
Mayutharan Balachandran
- Department of Intensive Care, Monash Health, Clayton, Victoria, Australia; The Victorian Heart Hospital, Clayton, Victoria, Australia
https://orcid.org/0000-0001-7071-4031
Yahya Shehabi
- The Victorian Heart Hospital, Clayton, Victoria, Australia; Monash Health School of Clinical Sciences, Clayton, Victoria, Australia; Clinical School of Medicine, University of New South Wales, Prince of Wales Hospital, Randwick, New South Wales, Australia
pdf